NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

MURA

Mural Oncology plc

May 19 • 04:00PM ET

2.80

Dollar change +0.15
Percentage change 5.66	%

Healthcare • Biotechnology • Ireland • NASD

Peers: MRNA BMY PFE GILD AMGN LLY JNJ AZN REGN BNTX

| Held by: VTI VXF LFSC VHT IWC MEDX BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.67	Insider Own	20.20%	Shs Outstand	17.26M	Perf Week	6.06%
Market Cap	48.35M	Forward P/E	-	EPS next Y	-2.22	Insider Trans	-0.73%	Shs Float	13.80M	Perf Month	3.70%
Income	-130.73M	PEG	-	EPS next Q	-1.99	Inst Own	51.86%	Short Float	7.00%	Perf Quarter	-35.03%
Sales	0.00M	P/S	-	EPS this Y	29.46%	Inst Trans	-5.65%	Short Ratio	0.21	Perf Half Y	-20.45%
Book/sh	6.25	P/B	0.45	EPS next Y	58.42%	ROA	-66.10%	Short Interest	0.97M	Perf Year	-27.27%
Cash/sh	6.24	P/C	0.45	EPS next 5Y	40.79%	ROE	-76.27%	52W Range	0.95 - 4.74	Perf YTD	-13.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-120.28%	52W High	-40.93%	Beta	3.28
Dividend TTM	-	Quick Ratio	5.08	Sales past 5Y	5.55%	Gross Margin	-	52W Low	194.74%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	5.08	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	61.82	Volatility	5.83% 5.18%
Employees	116	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.33	Target Price	11.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-4.84%	Payout	-	Rel Volume	0.05	Prev Close	2.65
Sales Surprise	-	EPS Surprise	-1.11%	Sales Q/Q	-	Earnings	Mar 11 AMC	Avg Volume	4.70M	Price	2.80
SMA20	6.71%	SMA50	13.53%	SMA200	-14.44%	Trades		Volume	256,874	Change	5.66%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-25	Downgrade	Raymond James	Strong Buy → Outperform	$18
Mar-25-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$15
Apr-04-24	Initiated	Morgan Stanley	Overweight	$13

Today 03:57PM	Mural Oncology Announces Number of Relevant Securities in Issue (GlobeNewswire) +5.66%
Apr-30-25 03:07PM	FORM 8.1(a) & (b) - Mural Oncology plc (GlobeNewswire)
Apr-16-25 09:48AM	MURA Soars as it Explores Strategic Options Post Cancer Study Failures (Zacks)
Apr-15-25 08:00AM	Mural Oncology Announces Plans to Explore Strategic Alternatives (GlobeNewswire) +133.98%
Mar-28-25 11:13AM	Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects (Seeking Alpha) -12.59%
06:30AM	Loading…
Mar-25-25 06:30AM	Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer (GlobeNewswire) -61.62%
Mar-11-25 04:01PM	Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones (GlobeNewswire)
Feb-18-25 07:00AM	Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-09-25 04:00PM	Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts (GlobeNewswire)
Dec-03-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-24 06:10AM	Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-20-24 04:15PM	Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer (GlobeNewswire)
Nov-13-24 07:00AM	Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress (GlobeNewswire)
Nov-11-24 07:00AM	Mural Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 04:15PM	Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
04:15PM	Loading…
Nov-04-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-24 07:00AM	Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Oct-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-24 07:00AM	Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress (GlobeNewswire) -5.31%
Sep-23-24 07:00AM	Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi (GlobeNewswire)
Sep-10-24 07:00AM	Mural Oncology to Host First Virtual Investor Day on September 26, 2024 (GlobeNewswire)
Sep-04-24 04:30PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-24 07:00AM	Mural Oncology to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:15AM	Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress (GlobeNewswire)
Aug-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.90%
Jul-31-24 07:00AM	Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors (GlobeNewswire) +5.03%
Jul-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 04:15PM	Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference (GlobeNewswire)
Jun-04-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.28%
May-23-24 05:00PM	Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
01:55PM	Loading…
May-14-24 01:55PM	MURA Stock Earnings: Mural Oncology Reported Results for Q1 2024 (InvestorPlace)
07:00AM	Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-24-24 04:00PM	Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-09-24 04:00PM	Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-04-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.87%
Mar-26-24 01:53PM	MURA Stock Earnings: Mural Oncology Reported Results for Q4 2023 (InvestorPlace)
07:00AM	Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-24 04:35PM	Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-04-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-24 07:00AM	Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-05-24 04:30PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-24 07:00AM	Mural Oncology Announces Enhancements to Late-Stage Clinical Trials (GlobeNewswire)
Dec-18-23 11:52AM	MURA Stock Earnings: Mural Oncology Reported Results for Q3 2023 (InvestorPlace)

Mural Oncology Plc is a clinical-stage oncology company, which focuses on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Loew Caroline	Officer	Mar 04 '25	Proposed Sale	3.36	4,313	14,491		Mar 05 05:10 PM
Keson-Brookes Maiken	See Remarks	Mar 05 '25	Sale	3.45	1,469	5,068	73,564	Mar 05 04:49 PM
Keson-Brookes Maiken	See Remarks	Mar 04 '25	Sale	3.36	1,262	4,240	75,033	Mar 05 04:49 PM
Loew Caroline	Chief Executive Officer	Mar 04 '25	Sale	3.36	4,313	14,492	305,590	Mar 05 04:48 PM
Maiken Keson-Brookes	CLO	Mar 05 '25	Proposed Sale	3.43	1,469	5,039		Mar 05 04:03 PM
Goodman Vicki L	Chief Medical Officer	Feb 24 '25	Sale	3.89	13,186	51,294	54,763	Feb 25 04:03 PM
Vicki Goodman	Officer	Feb 24 '25	Proposed Sale	4.04	13,186	53,271		Feb 24 04:11 PM
Keson-Brookes Maiken	See Remarks	Dec 23 '24	Sale	3.27	2,555	8,355	41,295	Dec 26 04:02 PM
Maiken Keson-Brookes	CLO	Dec 23 '24	Proposed Sale	3.25	2,555	8,304		Dec 23 04:19 PM
Loew Caroline	Chief Executive Officer	Dec 17 '24	Sale	3.40	2,763	9,394	237,628	Dec 18 04:06 PM
Goodman Vicki L	Officer	Nov 07 '24	Proposed Sale	3.33	5,069	16,870		Nov 08 04:03 PM
Goodman Vicki L	Chief Medical Officer	Nov 07 '24	Sale	3.33	5,069	16,880	67,949	Nov 08 04:02 PM
Cutler Adam D.	Officer	Oct 31 '24	Proposed Sale	3.41	7,421	25,306		Nov 01 07:08 AM
Cutler Adam D.	Chief Financial Officer	Oct 31 '24	Sale	3.41	7,421	25,306	71,438	Nov 01 07:04 AM
ALTSCHULLER Susan	Director	Aug 14 '24	Buy	3.21	10,000	32,071	10,000	Aug 15 04:15 PM
Keson-Brookes Maiken	See Remarks	Jul 18 '24	Sale	3.41	2,157	7,355	43,850	Jul 18 04:04 PM
Loew Caroline	Chief Executive Officer	Jul 08 '24	Sale	2.91	12,531	36,465	240,391	Jul 08 08:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MURA

Mural Oncology plc

Upgrade your FINVIZ experience